BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35513899)

  • 1. Intraocular Peak Pressure in Patients Under Treatment With Fixed Combination of Bimatoprost/Timolol/Brimonidine Once Daily Versus Twice Daily.
    Susanna BN; Susanna CN; Susanna FN; Mota RT; Barbosa GCS; Lima VL; Susanna R
    J Glaucoma; 2022 Oct; 31(10):e96-e100. PubMed ID: 35513899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
    García-López A; Paczka JA; Jiménez-Román J; Hartleben C
    BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
    Belfort R; Paula JS; Lopes Silva MJ; Della Paolera M; Kim T; Chen MY; Goodkin ML
    Clin Ther; 2020 Feb; 42(2):263-275. PubMed ID: 32089329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures.
    Solish AM; DeLucca PT; Cassel DA; Kolodny AH; Hustad CM; Skobieranda F
    J Glaucoma; 2004 Apr; 13(2):149-57. PubMed ID: 15097262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Switching From Latanoprost to Bimatoprost in Primary Open-Angle Glaucoma Patients Who Experienced Intraocular Pressure Elevation During Treatment.
    Germano RA; Susanna R; De Moraes CG; Susanna BN; Susanna CN; Chibana MN
    J Glaucoma; 2016 Apr; 25(4):e359-66. PubMed ID: 26900825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial.
    Brandt JD; VanDenburgh AM; Chen K; Whitcup SM;
    Ophthalmology; 2001 Jun; 108(6):1023-31; discussion 1032. PubMed ID: 11382623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
    Katz LJ
    Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
    Natt NK; Gupta A; Singh G; Singh T
    Indian J Ophthalmol; 2014 Dec; 62(12):1136-40. PubMed ID: 25579357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
    Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).
    Bacharach J; Tatham A; Ferguson G; Belalcázar S; Thieme H; Goodkin ML; Chen MY; Guo Q; Liu J; Robinson MR; Bejanian M; Wirta DL;
    Drugs; 2021 Nov; 81(17):2017-2033. PubMed ID: 34724172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension.
    Hommer A;
    Eur J Ophthalmol; 2007; 17(1):53-62. PubMed ID: 17294383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure.
    Sherwood M; Brandt J;
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S361-8. PubMed ID: 11434939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
    Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
    Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
    Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
    Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination.
    Alezzandrini A; Hubatsch D; Alfaro R
    Adv Ther; 2014 Sep; 31(9):975-85. PubMed ID: 25138224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.